- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05097261
Ketamine in Acute Brain Injury Patients. (BIKe)
Brain Injury and Ketamine: a Prospective, Randomized Controlled Double Blind Clinical Trial to Study the Effects of Ketamine on Sedative Sparing and Intracranial Pressure in Traumatic Brain Injury Patients.
Although, in the past years, an increasing use of ketamine in Traumatic Brain injury (TBI) has been reported as an adjunct to other sedatives, there is no evidence from randomized clinical trial to support this practice.
The BIKe (Brain Injury and Ketamine) study is a double-blind placebo controlled randomized multicenter clinical trial to examine the safety and feasibility of using ketamine as an adjunct to a standard sedative strategy in TBI patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study the effects of ketamine as an adjunct to an standard sedation regime in adult TBI patients will be investigated on the therapy intensity level and intracranial pressure. All patients will receive propofol for sedation to control ICP, to a maximum dose of 4 mg/kg/h. If the ICP is not controlled at the maximum dose of propofol, midazolam will be added, to a maximum dose of 0.3 mg/kg/h, as part of the current standard of care in the Participating Sites. All patients will receive remifentanil, fentanyl or sufentanil infusions for pain relief. The study medication (ketamine or placebo) will be started after randomization.
As part of the current standard of care in the Participating Sites, the decision for decompressive craniectomy and/or barbiturate coma will be taken after multidisciplinary consultation between the treating intensivist and neurosurgeon.
The decision to stop or reduce sedation, lies with the treating physician, based on the level of ICP control, the absence of clinical or radiological signs of deterioration of the neurologic state. In the case of barbiturate coma, the study drug will be discontinued. During and following decompressive craniectomy, the sedative regime (propofol/midazolam/study drug/ opioids) will be continued. In case of suspected or threatening Propofol-Related Infusion syndrome, propofol will be stopped and switched to midazolam. In case of hypertriglyceridemia >200 mg/dL, propofol will be reduced and if necessary, midazolam will be associated to allow control of sedation. During surgical procedures related to the traumatic brain injury or not, the study drug will not be discontinued. The use of open label administration of ketamine is not allowed during the course of the trial, i.e until hospital discharge.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Liese Mebis, PhD
- Phone Number: 003216343125
- Email: liese.mebis@uzleuven.be
Study Locations
-
-
-
Bonheiden, Belgium
- Recruiting
- Imelda Bonheiden
-
Contact:
- Emmanuel Van Der Hauwaert, MD
-
Brugge, Belgium
- Recruiting
- AZ Sint-Jan
-
Leuven, Belgium, 3001
- Recruiting
- UZLeuven
-
Contact:
- Liese Mebis, PhD, MSc
- Phone Number: +3216343125
- Email: liese.mebis@uzleuven.be
-
Principal Investigator:
- Geert JP Meyfroidt, MD, PhD
-
Sub-Investigator:
- Veerle De Sloovere, MD
-
Liège, Belgium
- Recruiting
- CHU de Liège
-
Contact:
- Didier Ledoux, MD
-
Liège, Belgium
- Recruiting
- CHR de la Citadelle liege
-
Contact:
- Hugues Maréchal, MD
-
Roeselare, Belgium
- Recruiting
- AZ DELTA
-
Contact:
- Peiter Lormans, MD
-
Turnhout, Belgium
- Recruiting
- AZ Turnhout
-
Contact:
- Eva Boonen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Traumatic brain injury patients
- Age >= 18 years
- Admitted to the ICU
Within 72 hours after admission to the initial hospital:
- ICP monitoring in place (parenchymal probe, ventricular catheter, or both)
- Requiring sedation
Exclusion Criteria:
- Known pregnancy and/or lactation
- Imminent or actual brain death upon inclusion
- Allergy or intolerance to the study medication
- Pre-existing neurocognitive disorders, pre-existing congenital or non-congenital brain dysfunction.
- Inability to obtain informed consent
- Inclusion in an interventional randomised controlled trial of which the PI indicates that co-inclusion specifically in the BIKe study is prohibited.
- Therapy restriction code upon inclusion.
- Porphyria
- Glaucoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketamine
Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h. Study patients weighing over 120 kg will not exceed the maximum dose of 120mg/kg of ketamine. The study medication will be started within 6 hours after randomization. The IMP, ketamine, will be provided directly to each Participating Site by the official supplier of ketamine for Belgium (Pfizer). |
Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted.
The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
Other Names:
|
Active Comparator: Placebo
The placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
|
Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in therapeutic intensity of intracranial pressure (ICP) reducing measures, assessed by the TIL score (Therapy Intensity Level)
Time Frame: From date of randomization (and start study drug) until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
The primary efficacy endpoint will be the reduction in daily Therapy Intensity Level (TIL) score, based on the highest score in each item per day until study drug discontinuation (calculated every day on the available data at 7:00 AM).
Scales for TIL score range from 0 (minimum) to 38 (maximum).
Higher scores are related to worse outcome.
|
From date of randomization (and start study drug) until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial pressure (ICP)
Time Frame: From date of randomization until study drug discontinuation or or date of death from any cause, whichever came first, assessed up to 6 months.
|
The average of hourly validated intracranial pressure (mmHg) measurements per 24 hours
|
From date of randomization until study drug discontinuation or or date of death from any cause, whichever came first, assessed up to 6 months.
|
Duration of sedation
Time Frame: defined as the start of the first infusion of either propofol, midazolam and/or dexmedetomidine to the cessation of the last uninterrupted infusion of either propofol, midazolam, opioids and/or dexmedetomidine, assessed up to 6 months.
|
Total duration of the first period of sedative treatments (propofol, midazolam and/or dexmedetomidine)
|
defined as the start of the first infusion of either propofol, midazolam and/or dexmedetomidine to the cessation of the last uninterrupted infusion of either propofol, midazolam, opioids and/or dexmedetomidine, assessed up to 6 months.
|
Propofol
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed at ICU discharge, assessed up to 6 months.
|
Total dose of propofol in mg per 24 hours
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed at ICU discharge, assessed up to 6 months.
|
Mechanical ventilation
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Total duration of mechanical ventilation, defined as all types of ventilation where positive end expiratory pressure is applied, expressed in cm H2O (5 cm H2O minimum).
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Midazolam
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Total dose of midazolam in mg per 24 hours
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
ICU length of stay
Time Frame: From ICU admission until ICU discharge (end of stay is defined as application for discharge in the hospital computer system, or death), assessed up to 6 months.
|
Length of stay (number of days) in ICU
|
From ICU admission until ICU discharge (end of stay is defined as application for discharge in the hospital computer system, or death), assessed up to 6 months.
|
Hospital length of stay
Time Frame: From admission to hospital until end of stay in hospital (dead or alive), assessed up to 6 months.
|
Length of stay in hospital (days)
|
From admission to hospital until end of stay in hospital (dead or alive), assessed up to 6 months.
|
Richmond Agitation-Sedation scale (RASS)
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Average daily RASS.
Scale ranges from +4 (combative) until -5 (Unarousable).
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Delirium
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Number of delirium-free days, assessed 3 times per day with the Intensive Care Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU (CAM-ICU delirium scale).
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
eGOS
Time Frame: 6 months after the onset of TBI
|
extended Glasgow Outcome Scale (eGOS)
|
6 months after the onset of TBI
|
ICU mortality
Time Frame: From date of randomization until ICU discharge, assessed up to 6 months.
|
Mortality during ICU stay
|
From date of randomization until ICU discharge, assessed up to 6 months.
|
In-hospital mortality
Time Frame: From date of randomization until hospital discharge, assessed up to 6 months.
|
Mortality during hospital stay
|
From date of randomization until hospital discharge, assessed up to 6 months.
|
Barbiturate coma incidence
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
The incidence of barbiturate coma
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Barbiturate coma duration
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
The duration of barbiturate coma
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Decompressive craniectomy
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months, assessed up to 6 months.
|
The incidence of decompressive craniectomy
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months, assessed up to 6 months.
|
Propofol Infusion Syndrome (PRIS)
Time Frame: From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Incidence of PRIS documented and diagnosed by the attending physician and defined as:
|
From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Wounds and Injuries
- Brain Injuries, Traumatic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- S60859
- 2017-004698-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Injuries, Traumatic
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
Eunice Kennedy Shriver National Institute of Child...CompletedTraumatic Brain Injuries
-
Technical University of MunichFederal Ministry of Defence (Germany); Bundesministerium der VerteidigungRecruitingTraumatic Brain InjuriesFrance, Germany
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of Alabama at BirminghamCompletedTraumatic Brain InjuriesUnited States
-
Seattle Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingConcussion, Brain | Brain Injury Traumatic MildUnited States
-
Washington University School of MedicineTerminated
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
Clinical Trials on Ketamine
-
Grace Lim, MD, MSNational Institute of Mental Health (NIMH)RecruitingPain, Postoperative | Depression, PostpartumUnited States
-
Ullevaal University HospitalUniversity of OsloCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedArthroplasty, Replacement, HipFrance
-
Assiut UniversityCompletedKetamine Causing Adverse Effects in Therapeutic UseEgypt
-
The University of Texas Health Science Center,...TerminatedPost Partum DepressionUnited States
-
Lotus Clinical Research, LLCiX Biopharma Ltd.Completed
-
Lawson Health Research InstituteUnknownBone Fractures | Dislocations
-
Antonios LikourezosCompleted
-
Children's Hospital of MichiganCompletedModerate, Deep Sedation